Herein,the rationale and supporting evidence for the promise of developing K+/Cl−co-transporter-2(KCC2)neuromodulatory therapies for spinal cord injury(SCI)is discussed.SCI is commonly a life-changing,unforeseen neuro t rauma that has devastating consequences for the injured person,their families and society as a whole.Because less than 1%of patients have a complete recovery,the vast majority of people after SCI have significant disabilities and can be entirely dependent upon others for assistance in their activities of daily living.The socioeconomic costs are a significant global burden,with SCI often occurring in adults during their peak earning years.Currently,there are no approved drugs that improve functional outcomes for people with SCI.Therefore,SCI commonly leads to a lifetime of disability,and new therapeutic approaches are urgently needed.
展开▼
